Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.

Journal of viral hepatitis - 1 Jul 2007

Zekri A R N, Haleem H A, Esmat G E-D, Bahnassy A A, El-Din H M A, Hafez M M, Sharaby A F, Sharaf H, Zakaria M S E-D

Abstract excerpt

Recent studies have indicated that cytokines can be used as markers for disease progression in hepatitis C virus (HCV)-infected patients, therefore this study was conducted to determine the influence of pegylated IFN vs standard IFN on interleukin-2 receptor (IL-2R), IL-6R, IL-8, TNFR-I, TNFR-II, sFas, and sFas-L in Egyptian patients with chronic hepatitis C genotype 4, as no previous studies have been performed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Fas Ligand Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fas Receptor

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Receptors, Tumor Necrosis Factor, Type II

Share to Ribavirin

Source

Identifiers

PMID: 17576388
DOI: 10.1111/j.1365-2893.2006.00832.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.PMID 17576388Read ↗

Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate.Semantic proximity Read ↗

Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C.Semantic proximity Read ↗

Inflammation and repair in viral hepatitis C.Semantic proximity Read ↗

Circulating Apo 2L levels decreased in genotype II hepatitis C with pegylated interferon-2 alpha treatment.Semantic proximity Read ↗

Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.Semantic proximity Read ↗

Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy.Semantic proximity Read ↗

Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4.Semantic proximity Read ↗

Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment.Semantic proximity Read ↗

Baseline profile of intrinsic cytokines predicting prognosis of chronic hepatitis B patients responding to HBV therapeutic vaccinationsSemantic proximity Read ↗

Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin.Semantic proximity Read ↗

High baseline interleukine-8 level is an independent risk factor for the achievement of sustained virological response in chronic HCV patients.Semantic proximity Read ↗

Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.